Supriya Lifescience Ltd. Reports Rs 145.07 Cr Revenue and 35.6% EBITDA Margin in Q1 FY26

API maker sees lower revenue in Q1 FY26 but maintains strong margins with growth expected in H2.

0 8 1 minute read

New Delhi | 20, August 2025 : Supriya Lifescience Ltd., a global API manufacturer with operations in over 86 countries, has shared its Q1 FY26 results. The company works across multiple therapeutic areas such as anti-histamine, anti-allergic, vitamins, anaesthetic, and anti-asthmatic products.

The company posted Rs 145.07 crore in revenue during Q1 FY26. This is a 9.7% drop compared to Rs 160.63 crore in Q1 FY25.

Strong Margins Despite Dip

EBITDA came in at Rs 51.70 crore, with a 35.6% margin. In Q1 FY25, EBITDA was Rs 62.54 crore with a 38.9% margin.

Profit After Tax (PAT) stood at Rs 34.79 crore, lower than Rs 44.64 crore last year. PAT margin was 24.0%, down from 27.8% in Q1 FY25.

Anaesthetic Segment Leads Growth

The anaesthetic segment contributed 53% to revenue, up from 45% in Q1 FY25.
The European market share grew to 41% of revenue, compared to 34% a year earlier.

Capacity utilisation rose to 76% in FY26, from 70% in FY25. To support expansion, Supriya Lifescience Ltd. purchased three new land parcels near its plants.

Chairman’s Statement

Mr. Satish Wagh, Chairman and Managing Director of Supriya Lifescience Ltd., said:

“Q1 was affected by repair and maintenance work at the Lote facility. These upgrades were needed to improve efficiency and to prepare Module E for new product launches. Despite lower revenue, margins stayed strong due to backward integration and higher sales from regulated markets. With the Ambernath site ready for production in Q4 and 3–4 product launches planned in FY26, we expect a strong recovery in the second half. We remain on track to achieve about 20% growth and cross Rs 1,000 crore revenue by FY27.”